Bristol Myers Squibb Adds Mirati Therapeutics to Its Oncology Portfolio – Merger Arbitrage Mondays –

The acquisition of Mirati Therapeutics (MRTX) by Bristol-Myers Squibb Company (BMY) for $5.8 billion equity value including the value of a CVR worth as estimated $1 billion.
Amgen (AMGN) completes the acquisition of Horizon Therapeutics Public Limited Company (HZNP).
Sen. Elizabeth Warren (D-MA) and Rep. Pramila Jayapal (D-WA) asks antitrust regulators to examine UnitedHealth Group’s (UNH) planned purchase of Amedisys (AMED).